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Abstract
The mechanism behind the growth and development of tumors is intensively studied using several mathe-
matical approaches that rely on linear and non-linear techniques to model the cell population dynamics to
better understand the development and progression of cancer. In this paper, we study the progression of a
type of malignant tumors characterized by the stem-diﬀerentiation hierarchy. Two main issues are modeled
and investigated: the diﬀerentiation phase and the phenotypic plasticity that suggests the existence of a
dynamic interaction among Cancer Stem Cells and non-Cancer Stem Cells populations. Using these mod-
els, we study several therapy eﬀects on breast cancer in order to obtain the temporal behavior of the cell
populations, taking into account diﬀerent drug concentrations and oncoantigen-driven vaccinations.
Keywords: Prediction of Cancer Stem Cells behaviour, Mathemathical approach, Biological processes
modelling.
1 Introduction
Several mathematical models describing many aspects of tumor malignancy, as well
as tumor growth, angiogenesis process, and drug response are published in the
literature [2,5,14].
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Recent studies have changed the traditional view of tumor progression, showing
that the growth and progression of many cancers are driven by small groups of Can-
cer Stem Cells (CSCs) [3]. Given this evidence, Turner et al [15] and Zhu et al [17]
developed two models that use systems of ordinary diﬀerential equations (ODEs)
to describe this new theory of tumor development. The CSC tumor model presents
a hierarchically structured organization similar to that found in normal tissues:
CSCs are self-renewing, capable of tissue regeneration and of giving rise to non-
CSCs, the latter being more diﬀerentiated and largely lacking in tissue-regeneration
ability. Considering this hierarchical structure, the response to drug treatments on
the several cell populations that compose the cancer, will produce diﬀerent eﬀects
depending on the characteristics of the cancer subpopulation. For this reason, the
CSCs are believed to be the cause of failure of conventional therapies, since eﬀective
drug treatments able to eliminate all the CSCs, hence to avoid relapses, are not easy
to ﬁnd [7].
Based upon the models presented in [17,15], we study the progression of malig-
nant tumors characterized by the stem-diﬀerentiation hierarchy. In particular, we
generalize their ODEs systems by taking into account all cancer types described by
this hierarchical model. Two main issues are investigated: (i) the diﬀerentiation
phase (in [17] the authors model only the proliferation phase of all subpopulations),
and (ii) the phenotypic plasticity that suggests the existence of a dynamic interac-
tion among CSCs and non-CSCs populations. In our ODEs system we also account
for the drug eﬀect on the cancer in order to simulate the behavior of the cells,
considering diﬀerent drug concentrations.
2 Model structure
In the last 15 years major advances have been made in the understanding of tumor
maintenance and initiation of relapse. These studies lead the researchers to move
from a traditional view of cancer organization to a new heterogeneity concept. The
traditional notion of cancer explains that the malignant tumor consists of a unique
type of cell population characterized by the ability to divide without limit. This
view has been overcome after the identiﬁcation of the CSCs that can diﬀerentiate
into heterogeneous cancer subpopulations.
In this section we describe the main biological features characterizing the tumor
hierarchical organization based on CSC theory (Section 2.1) and how we translate
these considerations into an ODEs model (Section 2.2).
2.1 Stem-diﬀerentiation hierarchy model
Several papers have been published, where the identiﬁcation and characterization
of CSCs has been reported [12,4]. The ability of CSCs to drive the growth and
regeneration of tumors can be understood by considering their main properties:
(i) tumorigenic capacity and self-renewal, (ii) tissue regeneration and (iii) diﬀeren-
tiation into non-stem cells. The CSCs abilities best characterize the cancer types
described by the stem-diﬀerentiation hierarchy’s model. Indeed, in these tumors the
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growth and the progression are driven by the CSCs subpopulations. Moreover, the
hierarchical organization of the tumor is guaranteed from the CSC diﬀerentiation
capacity. CSCs give rise to committed progenitor cells (PCs) which in their turn
give rise to cells characterized by a rapid proliferation rate which then originate
terminally diﬀerentiated cells (TCs).
A CSC is deﬁned as a cell that can divide either symmetrically (originating two
cells of the same CSC type) or asymmetrically (i.e., giving rise to a CSC cells and
to a PC cell) upon the issuing of an appropriate external signal. Although it is
still unknown what might be the mechanism for controlling whether a stem cell
divides symmetrically or asymmetrically, empirical evidence shows that some envi-
ronmental conditions could inﬂuence this phenomenon, so that, becomes crucial the
micro-environment, also called niches, where the CSCs reside. Environmental pres-
sures result in constantly adapting the cell physiology and gene expression for the
appropriate stem cell state [8]: indeed, when moving from CSCs to TCs, it is possi-
ble to observe the existence of diﬀerent niche compositions leading to a progressive
loss of proliferation ability, pluripotency and metastatic potential [1]. Moreover, in
response to environment signals it is possible that during their early stage PCs can
diﬀerentiate into CSCs. The possibility of bidirectional interconvertibility is due to
some contextual signals that reprogrammed the non-CSCs into CSCs [6].
Due to this cancer structure, the stem-diﬀerentiation hierarchy model aﬀects the
design of cancer therapies. For instance, many papers [16,9] report the resistance
of CSCs to many current cancer treatments including chemo and radiation ther-
apy, while these therapies reveal a positive eﬀect on TCs. Treatments designed to
eliminate only TC subpopulation will likely be unsuccessful from the point of view
of having a clinical impact on the whole tumor. Indeed, if the treatments fail in
killing the CSCs, there is a large possibility to regenerate new tumors. Novel cancer
therapies must consider these dynamics and must thus be designed to account for
both genetic alterations and diﬀerentiation states of the CSCs in order to eradicate
them.
2.2 The cancer ordinary diﬀerential equations system
As described in the previous section, the hierarchical model is composed of three
cellular subpopulations: CSCs, PCs and TCs. The ﬁrst two subpopulations are
characterized by similar dynamics which are based on the succession of two phases:
proliferation and diﬀerentiation, as shown in Figure 1 (A).
Proliferation rate is described by the parameter ω while diﬀerentiation rate is
described by the parameter η. γ represents the parameter of the ability of progenitor
cells to acquire CSC phenotype, also called dediﬀerentiation. All the subpopulations
will die at a certain rate represented by the parameter d.
In Figure 1(B) is reported the detailed representation of the proliferation and
diﬀerentiation mechanisms for each subpopulations. The CSCs can divide in both
symmetrically or asymmetrically ways to generate two CSCs or one CSC and one
PC1, respectively. On the other hand, the PCs subpopulation can evolve through
several stages. At each stage the PC cells can proliferate in a symmetric manner
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Fig. 1. Cancer stem cells model. (A) CSCs and PCs cycle (B) Details of proliferation and diﬀerentiation
rules
producing two PC cells belonging to the next stage. Following the assumptions
made by Zhu [17], we set to seven the number of stages. For what concerns the
diﬀerentiation, the CSC becomes PC1 while a subpopulation PC at stage i (PCi),
diﬀerentiates in the PC of the next stage (PCi+1). Finally, the last stage of PC,
PC7, is diﬀerentiated in TC cells. As described in the previous section, we also
model the bidirectional inter-convertibility among CSCs and PCjs. This plasticity
involves the ﬁrst three generation of PCs that are still similar to CSCs. Therefore
we speculated that only some PC’s stages can undergo dediﬀerentiation to CSC,
with a rate described by the parameter γ [15].
Finally, we also consider the eﬀect that drug exposure may have on cancer. The
drugs that we consider are either chemical compounds or current cancer treatments,
including chemo and radiation therapies or vaccine administrations. Considering
these diﬀerent types of treatments we are conﬁdent to suppose that all the subpop-
ulations are subject to at least one drug action. We model the drug eﬀects as an
increment of the cell diﬀerentiation rate, thereby accelerating the generation of the
next subpopulation. The intensity of the drug exposure is captured in the model
by the proper setting of parameter Θ.
Accounting for all these considerations, a model of the dynamics of these cancer
cell populations is constructed by specifying the following system of linear and
homogeneous ODEs:
dNCSC
dt
= PsyωCSCNCSC + γPC
3∑
j=1
NPCj − η1NCSC −Θ1NCSC − d1NCSC
dNPC1
dt
= PasyωCSCNCSC − ωPCNPC1 − γPCNPC1 + η1NCSC − η2NPC1 +
+Θ1NCSC −Θ2NPC1 − d2NPC1
dNPCj
dt
= 2ωPCNPCj−1 − ωPCNPCj − γPCNPCj + η2NPCj−1 − η2NPCj +
+Θ2NPCj−1 −Θ2NPCj − d2NPCj j = 2...3
(1)
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dNPCi
dt
= 2ωPCNPCi−1 − ωPCNPCi + η2NPCi−1 − η2NPCi +Θ2NPCi−1 −
−Θ2NPCi − d2NPCi i = 4...6
dNPC7
dt
= 2ωPCNPC6 + η2NPC6 − η3NPC7 +Θ2NPC6 −Θ2NPC7 − d2NPC7
dNTC
dt
= η3NPC7 +Θ2NPC7 −Θ3NTC − d3NTC
where NCSC , NPCi and NTC are the numbers of cancer stem cells, progenitor cells,
and terminal cells, respectively.
Notice that the terms characterizing these equations depend on 5 parameters:
(i) ωCSC , ωPC : describes the proliferation rate of all the subpopulations, except
for TCs. Note that all the PC subpopulations are modeled by a positive and
negative term in order to describe their symmetric proliferation in the next
stage of PCs. The proliferation rates of CSC and PC1 depend also on Psy and
Pasy that are the probabilities of symmetric and asymmetric CSC division[17],
respectively.
(ii) γPC : represents the bidirectional inter-convertibility parameter that involves
CSC, PC1, PC2 and PC3 subpopulations.
(iii) di: indicates the death rate speciﬁc for each individual subpopulation i.
(iv) ηi: describes the diﬀerentiation rates of each individual subpopulation i. Since
the diﬀerentiation process involves all the subpopulations in the ordered chain
of evolution, CSC → PCi → TC, in all the equations except those concerning
CSCs and TCs, both positive and negative terms are included.
(v) Θi: indicates the drug eﬀects for each individual population i. As explained
before, we model the eﬀects of the drug therapy as increments of diﬀerentiation
rates: indeed, the Θ-terms follow the same trend of η-terms. Moreover, a
speciﬁc parameter Θ3 is deﬁned for the TC subpopulation in order to describe
the eﬀect of treatments that work speciﬁcally on TCs.
3 Equilibrium analysis
The overall behavior of the tumor progression discussed in this paper is studied by
developing an analytic solution of the system of ODEs described in the previous
section on the basis of diﬀerent combinations of model parameters. Our ﬁrst objec-
tive is to determine which values lead to an equilibrium trend. For this purpose, the
steady state analysis of the model can be exploited to identify key parameter groups
and to establish which parameters aﬀect most the dynamics of subpopulations.
3.1 Basic Model Solution
The linear system of ODEs (1) described in the previous section can be expressed
in the following matrix form:
Z
′
= AZ (2)
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where matrix A contains the coeﬃcients of the biological system, while vector Z
refers to the variables that represent the cell subpopulations. The solution of (2) is
given by a linear combination of terms of the following form:
Zi = Wie
λit (3)
where Wi is the i − th eigenvector of A and λi is its corresponding eigenvalue.
The solution of the ODEs system is thus reduced to compute the eigenvectors and
eigenvalues of matrix A, see [11] for more details. Following the analysis approach
proposed by Zhu in his paper [17], we ﬁrst concentrate on the study of the steady
state behavior of this model. Our description of the dynamics of tumor progression
builds on Zhu’s model accounting for diﬀerentiation, feedback (bidirectional inter-
convertibility) and drug treatments. Neglecting all these aspects, the steady state
analysis performed by Zhu shows that the equilibrium is obtained by setting:
PsyωCSC = d1 (4)
This result conﬁrms the key role of CSCs in tumor growth: all cell populations
reach a steady state if and only if the proliferation of CSCs is kept under control. In
Zhu’s model this equilibrium condition is guaranteed when the rate of the symmetric
division – that leads to an eﬀective increment of the CSCs concentration – is set
equal to the CSCs death rate; in real cases, instead, the control of the proliferation
of CSCs depends also on diﬀerentiation, feedback, and drug treatments.
3.2 Our model analysis
For the above reasons, we propose a more detailed biological model that results
in a system of linear ODEs whose analytical solution is harder to compute. The
diﬃculty of this task is mainly caused by the presence of the feedback eﬀect which
can be however overcome by following a step-by-step procedure that we explain
next. To make the analysis easier, we ﬁrst study a simpliﬁed version of the model
which neglects the feedback and then we extend the solution to the more general
case. In details, we consider three variants of the model: (var1) corresponds to the
system of ODEs with nine subpopulations (described in Section 2.2 ), but without
the representation of the feedback; (var2) is the system of ODEs accounting only
for the CSC and PC1 subpopulations, but with the representation of the feedback;
(var3) is the whole system corresponding to Eq. (1).
The equilibrium of the var1 system is assured by the following condition:
PsyωCSC = d1 + η1 +Θ1 (5)
Indeed, this system is only a marginal generalization of Zhu’s model and the CSCs
proliferation is controlled by the death, diﬀerentiation, and drug treatments rates.
Considering the system var2, that takes into account the feedback action only on
CSC and PC1 subpopulations, the steady state condition is computed solving a
second degree polynomial. The equilibrium condition is given by:
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A =
B
C
γ where
⎧⎪⎨
⎪⎩
A = PsyωCSC − d1 − η1 −Θ1
B = PasyωCSC + η1 +Θ1
C = −ωPC − η2 − γPC −Θ2 − d2
From a biological point of view, this expression means that the decay of the CSC
population is kept under control if the combined value of death, diﬀerentiation, and
drug treatment rates exceeds the proliferation rate (the term denoted with A),
as long as the feedback coming from the bidirectional inter-convertibility of PC1
(represented B/C and γ) compensates the diﬀerence. In the case of var2, the CSC
variation is expressed by a group of parameters (PsyωCSC , d1, η1 and Θ1) and it
has to be balanced by the CSC surrogate production given by the feedback action
that is proportional to the concentration of PC1.
From a biological point of view, this expression means that the equilibrium of
the system is reached if the CSCs ”cycle” – deﬁned as proliferation, death, diﬀeren-
tiation, drug eﬀect, and denoted with A– is balanced with respect to the PC1 cycle
and the feedback (represented by B/C and γ respectively). In the case of var2, the
CSC variation is expressed by a group of parameters (PsyωCSC , d1, η1 and Θ1) and
it has to be balanced by the CSC surrogate production given by the feedback eﬀect
that is proportional to the concentration of PC1.
Finally, the computation of the eigenvectors and eigenvalues of matrix A for the
systems corresponding to var3 is more complicated since we must solve a cubic
polynomial. The analytic solution of this polynomial is diﬃcult to manage [10],
hence we adopt a graphical approach to determine its roots. We estimate the
equilibrium condition of var3 as the following:
A ≈ B
C
γ
(
1 +
(
D
C
)2
− D
C
)
where
⎧⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎩
A = PsyωCSC − d1 − η1 −Θ1
B = PasyωCSC + η1 +Θ1
C = −ωPC − η2 − γPC −Θ2 − d2
D = 2ωPC + η2 +Θ2
In the complete ODEs system the ﬁrst three generations of progenitor cells are
able to dediﬀerentiate into CSCs cells. Hence, as explained for the var2 case, the
CSCs variation must be balanced considering the PC1, PC2 and PC3 cycles.
4 Results
In this section we ﬁrst report the comparison between the results presented in Zhu’s
paper [17] and those provided by our system (Eq.(1)) in order to verify that our
model is able to replicate the system qualitative behavior by exploiting the same
parameter set.
The model is subsequently applied to study the dynamics of a stem-
diﬀerentiation hierarchy cancer, i.e. the breast cancer. The model parameters are
tuned by using experimental data; the resulting model setting is used to investigate
several drug eﬀects and their combination. In all ﬁgures we show the temporal
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behavior of three subpopulations: CSCs, TCs, and the sum of all the seven stages
of progenitors indicated by PCs. Moreover, all numerical solutions (referred to as
simulations) of the ODEs have been performed assuming the presence of a single
CSC at time zero.
4.1 Models comparison
We run our model by using the same parameter set adopted by Zhu and coworkers
that is based on experimental data or extracted from scientiﬁc literature. 6
Fig. 2. Comparison of equilibrium conditions and expansion among Zhu’s model and our model. (A,B)
Steady state condition of the tumor in which the number of CSCs, PCs, and TCs reach constant values.
(C,D) Expansion of the three subpopulations over time.
Since we are interested to evaluate the level of similarity existing between the
results published by Zhu and those derived by our model, we neglect in this phase,
the drug eﬀects. Figure 2 (A, C) show the dynamics of the three subpopulations
using Zhu’s model, whereas Figure 2 (B, D) report the subpopulations trend ob-
tained with our model. Panels A and B are obtained by setting the equilibrium
conditions. Note that the qualitative behavior is similar, while the absolute values
reached in equilibrium by the subpopulations are diﬀerent. This diﬀerence is easy
to explain since it is mainly due to the introduction of the feedback eﬀect which is
not represented in Zhu’s model.
6 Some of these parameters where reported with obvious typographical errors since they had in some
cases wrong units of measurement. In Table at http://compsysbio.di.unito.it/supplementary_material/
ODEModel.php we report the correct version of them.
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On the other hand, in panels C and D are depicted the expansions of the three
subpopulations obtained by relaxing the equilibrium conditions. The previous con-
siderations concerning the qualitative and quantitative behaviors of the two models
are valid also in this case. Indeed, decreasing the symmetric division probability
value in Zhu’s model, it is possible to observe an expansion of CSCs population that
leads to an increment of PCs and TCs. In our model, in order to observe a slow
increment of all the three subpopulations, the self-renewal and feedback rates must
be faster than those of death and dediﬀerentiation.
4.2 Simulating the eﬀect of atorvastatin on vaccination in breast cancer
In this section we present the simulation results obtained when we take into ex-
plicit consideration the drug eﬀects. Note that, Zhu and coworkers perform some
experiments in order to understand the tumor response to diﬀerent treatments, but
their preliminary approach consisted of the simulation of the drug eﬀect by a rather
simplistic increment of the death rates of PCs and TCs subpopulations.
Instead, we insert three speciﬁc parameters, one for each subpopulation, de-
scribing a cancer therapy. We use our model to study the eﬀect of the adjuvant
treatment and the oncoantigen-driven vaccination on breast cancer.
The parameter set used in our model, without accounting for the drug eﬀects,
is retrieved by tuning the system to reach 35 TCs cells at 1000 hours. This value
is derived by the tumor mass growth trend observed in mice after a subcutaneous
injection of 100.000 cancer cells [Personal communication]. The resulting model
calibration reveals a fast increment of TCs and PCs cells as reported in Figure 3
(A).
We use this model speciﬁcation to simulate the vaccination eﬀect on the tumor
growth; note that the vaccination is performed at 2000 hours. In particular, the
Θ3 value is set in order to obtain a reduction of 50% of TCs in about
500 hours with respect to the normal tumor growth (see Figure 3, panel
A). A mass reduction of 50% is resonable with respect to the decrement
trend observed in vaccination experiments made on mice having tumors
with 4 mm diameter. Indeed, in Figure 3 (B) it is possible to observe a strong
reduction in the number of TCs at 2000 hours. However, since the vaccination acts
only on TCs, the CSCs follow the normal cancer growth and thus after 500 hours
the increment of TCs increases again.
A diﬀerent behavior is observable when we simulate the eﬀect of atorvastatin on
CSCs acting on the parameter Θ1 only. Atorvastatin is a cholesterol lowering drug
with antileukemic eﬀects [13]. In vitro experiment of atorvastatin eﬀects suggests
its role on the inhibition of CSCs functionalities. We set the value of Θ1 in order
to obtain a reduction of 50% of CSCs which corresponds to the administration of
5μM of drug. Panel 3(C) reports the atorvastatin eﬀect given at 2000 hours: notice
that the number of CSCs decreases and, as consequence, also the number of TCs, at
5000 hours, is less than 50% with respect to the normal condition of cancer growth.
Finally, panel 3(D) reports the simulation of vaccine and atorvastatin treatment
performed at the same time (2000 hours). Notice that in this case all the three
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Fig. 3. Simulation of breast cancer growth without drugs (A), considering the ErbB2 vaccination eﬀect
(B), the eﬀect of 5μM of atorvastatin (C) and the combination of vaccination and atorvastatin (D); eﬀect
of atorvastatin on CSC and the ﬁrst three generation of progenitor subpopulations in conjunction with
vaccination(E)
subpopulations decrease: at 5000 hours the number of TCs is 44% and 68% less
than vaccination only and atorvastatin therapy only, respectively.
Panel 3(E) reports the temporal behavior of the three subpopulations consider-
ing the vaccination therapy and atorvastatin eﬀect on both CSCs and PCs. Indeed,
we add an additional eﬀect of atorvastatin on the ﬁrst three generations of PCs,
which are able to generate CSCs by a feedback action. We simulate this case
properly setting Θ2, i.e. using Θ2 = 0 for the ﬁrst three PCs, and Θ2 = 0
for the others . It is worthwhile to note that if the atorvastatin eﬀect involves
also the ﬁrst stages of PCs, the subpopulations increment after the administration
is much slower with respect to the trend observed in plot D. These results are now
under validation with in-vivo experiments concerning mice challenged with CSC
and treated with vaccination and atorvastatin.
5 Discussion and perspective
We present an ODEs system to describe the dynamics of the cancer cell subpopula-
tions involved in the cancer type belonging to stem-diﬀerentiation hierarchy model.
We ﬁrst determine the values of the parameters that lead the system to an
equilibrium behavior. Subsequently, we simulate the vaccination and drug therapy
eﬀects on the tumor growth. We plan to deeply study the eﬀect of each parameter
involved in the equilibrium of the system. Considering the key parameter groups
deﬁned in the paper, we would like to identify which parameters aﬀect mostly the
dynamics of subpopulations. We also plan to setup the vaccination protocol in
presence of increasing concentrations of Atorvastatin.
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